[
  {
    "ts": null,
    "headline": "AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND",
    "summary": "Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the first quarter of 2026. The dividend will be paid on March 6, 2026, to all stockholders of record as of the close of business on February 13, 2026.",
    "url": "https://finnhub.io/api/news?id=51e8bdeec1a8f762573bfaa9f85358197e63b8979ec2f6852858bfa9ae989ece",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765314060,
      "headline": "AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND",
      "id": 137750213,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the first quarter of 2026. The dividend will be paid on March 6, 2026, to all stockholders of record as of the close of business on February 13, 2026.",
      "url": "https://finnhub.io/api/news?id=51e8bdeec1a8f762573bfaa9f85358197e63b8979ec2f6852858bfa9ae989ece"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Pause Ahead of Fed Decision on Rates",
    "summary": "The stock market was struggling to hold onto even modest gains on Tuesday. The Dow was down 111 points, or 0.2%. The S&P 500 was up just 0.1%. The Nasdaq Composite was up 0.2%. Though a slim majority of stocks in the S&P 500 were up on the day, market breadth was slipping.",
    "url": "https://finnhub.io/api/news?id=8617b88bb0cb339ca9bfd8190bb84454a2ff6ce8955dbc51b857254b11786600",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765304519,
      "headline": "Stocks Pause Ahead of Fed Decision on Rates",
      "id": 137750215,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The stock market was struggling to hold onto even modest gains on Tuesday. The Dow was down 111 points, or 0.2%. The S&P 500 was up just 0.1%. The Nasdaq Composite was up 0.2%. Though a slim majority of stocks in the S&P 500 were up on the day, market breadth was slipping.",
      "url": "https://finnhub.io/api/news?id=8617b88bb0cb339ca9bfd8190bb84454a2ff6ce8955dbc51b857254b11786600"
    }
  },
  {
    "ts": null,
    "headline": "Columbus’s Reputation as an Affordable City Is Making Its Homes More Expensive",
    "summary": "The city’s Goldilocks status as an employer magnet with still-reasonable housing is now on shaky ground.",
    "url": "https://finnhub.io/api/news?id=f3d9b955227833202241645b784dc85604af1ff6547083e03bf1b003e0c83eeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765299960,
      "headline": "Columbus’s Reputation as an Affordable City Is Making Its Homes More Expensive",
      "id": 137742743,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The city’s Goldilocks status as an employer magnet with still-reasonable housing is now on shaky ground.",
      "url": "https://finnhub.io/api/news?id=f3d9b955227833202241645b784dc85604af1ff6547083e03bf1b003e0c83eeb"
    }
  },
  {
    "ts": null,
    "headline": "Global Market for Merkel Cell Carcinoma Driven by Key Players Like Merck & Bristol Myers Squibb",
    "summary": "The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly affecting older adults, is increasingly being treated with immune checkpoint inhibitors like Keytruda and Opdivo, which have revolutionized patient survival rates. The market faces challenges with the high cost of treatments impacting accessibility. Key players such as Merck, Bristol Myers Squibb, a",
    "url": "https://finnhub.io/api/news?id=96338e445ef0d15113a47f0fd5daf51bbc8e1ebf5744e5557f3cc8964b1e7c2d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765292280,
      "headline": "Global Market for Merkel Cell Carcinoma Driven by Key Players Like Merck & Bristol Myers Squibb",
      "id": 137742694,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The global Merkel Cell Carcinoma (MCC) market is rapidly evolving, driven by advancements in immunotherapy and a surge in early diagnoses. Merkel cell carcinoma, a rare, aggressive skin cancer mainly affecting older adults, is increasingly being treated with immune checkpoint inhibitors like Keytruda and Opdivo, which have revolutionized patient survival rates. The market faces challenges with the high cost of treatments impacting accessibility. Key players such as Merck, Bristol Myers Squibb, a",
      "url": "https://finnhub.io/api/news?id=96338e445ef0d15113a47f0fd5daf51bbc8e1ebf5744e5557f3cc8964b1e7c2d"
    }
  },
  {
    "ts": null,
    "headline": "Moat Stocks Gain On Health Care Strength, Tech Slowdown",
    "summary": "Moat Index gained 1.53% in November, supported by health care and broader market participation.\nMerck and Amgen were top Moat Index contributors, benefiting from strong demand and pipelines.",
    "url": "https://finnhub.io/api/news?id=2ea8abce7d23f3dd04e56d1e25e81f5ded986f8c0fd4f22e4f8ff4587ef88700",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765257960,
      "headline": "Moat Stocks Gain On Health Care Strength, Tech Slowdown",
      "id": 137738946,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/976507484/image_976507484.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Moat Index gained 1.53% in November, supported by health care and broader market participation.\nMerck and Amgen were top Moat Index contributors, benefiting from strong demand and pipelines.",
      "url": "https://finnhub.io/api/news?id=2ea8abce7d23f3dd04e56d1e25e81f5ded986f8c0fd4f22e4f8ff4587ef88700"
    }
  }
]